PORTFOLIO NEWS Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update April 13, 2023 Read More » Eikon Therapeutics Expands its Discovery Labs with Second Location in Hayward, California March 30, 2023 Read More » RAPT Therapeutics Announces Initiation of Phase 2A Trial of RPT193 in Patients with Moderate to Severe Asthma March 29, 2023 Read More » Remix Therapeutics Appoints Robert Gagnon as Chief Financial Officer March 22, 2023 Read More » Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress March 22, 2023 Read More » Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 March 20, 2023 Read More » Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in a Mouse Model of Atopic Dermatitis at the American Academy of Dermatology Annual Meeting March 16, 2023 Read More » ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates March 16, 2023 Read More » RAPT Therapeutics Reports Fourth Quarter and Year End Financial Results March 14, 2023 Read More » Ribon Therapeutics Doses First Patient In Phase 1 Clinical Study with RBN-3143 in Patients with Moderate to Severe Atopic Dermatitis March 9, 2023 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update April 13, 2023 Read More »
Eikon Therapeutics Expands its Discovery Labs with Second Location in Hayward, California March 30, 2023 Read More »
RAPT Therapeutics Announces Initiation of Phase 2A Trial of RPT193 in Patients with Moderate to Severe Asthma March 29, 2023 Read More »
Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress March 22, 2023 Read More »
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 March 20, 2023 Read More »
Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in a Mouse Model of Atopic Dermatitis at the American Academy of Dermatology Annual Meeting March 16, 2023 Read More »
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates March 16, 2023 Read More »
Ribon Therapeutics Doses First Patient In Phase 1 Clinical Study with RBN-3143 in Patients with Moderate to Severe Atopic Dermatitis March 9, 2023 Read More »
